Controlled Release Delivery Conference 2018

SMi Group21 - 22 March, London, UK.
An industry-leading show, SMi have been running this conference for 15 years - a testament of how vital this particular focus is to the biotech and pharma sector. As physicians and scientists continue to find strategies to assist in simplifying treatment schedules for patients, a pharma focus continues to move towards innovative controlled release technologies to improve drug transport to target.

Moreover, with the global oral controlled release drug delivery technology market expected to expand at 7.2% CAGR between 2017-2027 (with an estimated revenue of US$50B by 2027), now is the time to get ahead of the game by exploring and understanding innovations in drug delivery, nanoparticles/nanomedicine & QbD, CNS drug delivery and therapeutic application.

Who will be speaking?

  • Howard Stevens, Emeritus Professor, University of Strathclyde (CHAIRMAN)
  • Joël Richard, Senior Vice President, Peptides Development, Ipsen (CHAIRMAN)
  • Mohamed Albed Alhnan, Senior Lecturer, University of Central Lancashire
  • Pavel Farkas, Senior Director - Biopharmaceutics/ Clinical Development, PLIVA
  • Barry Friend, Sr. Technical Manager, Colorcon
  • Sebastian Schwier, Project Director / Int. Technical Project Leader, ‎Grünenthal
  • Karsten Lindhardt, CSO, Head R&D, Egalet
  • Teofilo Vasconcelos, Formulation Manager, Bial
  • Guillaume Saint-Pierre, Chief Executive Officer and Cofounder, PeptiGelDesign

Highlights this March 2018

  • Understand the impact of the current EU Guideline on clinical evaluation of modified release drugs from a pharmaceutical perspective, with a talk from PLIVA
  • Discover new technologies and innovations for the development of Controlled Release drugs including Lipid-composite microparticles, Molecular Envelope Technology (MET) nanoparticles and Abuse-Deterrent Formulations
  • Focus on Successful Oral Technologies progressing in the clinic, with talks discussing lessons learned from clinical studies
  • Learn about the advances and challenges in Paediatric controlled release formulations, including taste-masking and oral formulation challenges
  • ...and more.

For further information and to register, please visit:
https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...